<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833766</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 24/14</org_study_id>
    <nct_id>NCT02833766</nct_id>
  </id_info>
  <brief_title>Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer</brief_title>
  <official_title>Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to determine the efficacy of doxorubicin-loaded anti-EGFR
      immunoliposomes as first-line therapy in patients with advanced triple Negative, EGFR
      positive breast cancer. In this proof of concept trial, all patients will have an
      administration of the doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR-IL-dox) every
      28 days, until progression or unacceptable toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advanced triple negative breast cancer (TNBC) is a highly chemosensitive disease displaying a
      dismal short-term prognosis with more than three quarters of patients in progression 12
      months after the initiation of conventional chemotherapy. Approximately 2/3 of TNBC are
      expressing EGFR and breast cancer, including TNBC, is a disease highly sensitive to
      anthracyclines. Furthermore, data from a phase I trial, in 26 patients with different solid
      tumors, show very little toxicity and signs of efficacy of anti-EGFR-IL-dox.

      The EGFR assessment will be performed centrally and only patients with EGFR positive tumors
      will be included. The patients will be treated with the anti-EGFR-IL-dox until progression
      and followed-up according to standard practice for patient with TNBC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>at 12 months after registration</time_frame>
    <description>PFS is defined as the time from registration until progression according to RECIST v1.1 or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>at 12 months after registration</time_frame>
    <description>ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>at 12 months after registration</time_frame>
    <description>DOR is defined as time from the date when a patient first meets the criteria for CR or PR according to RECIST v1.1, until documented progression, relapse or death due to disease progression, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>at 12 months after registration</time_frame>
    <description>Time to Progression (TTP), defined as the time from registration until progression TTP assessed according to RECIST v1.1 or death due to disease progression, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>at 12 months after registration</time_frame>
    <description>PFS is defined as the time from registration until progression according to RECIST v1.1 or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 12 months after registration</time_frame>
    <description>OS is defined as time from registration until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>at 12 months after registration</time_frame>
    <description>AE are assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>anti-EGFR-IL-dox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastatic, non resectable, EGFR positive TNBC patients treated in first-line</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-EGFR-IL-dox</intervention_name>
    <description>First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days</description>
    <arm_group_label>anti-EGFR-IL-dox</arm_group_label>
    <other_name>anti-EGFR-immunoliposomes loaded with doxorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations before prescreening and
             registration and prior to any trial specific procedures, including participation in
             mandatory translational research

          -  Histologically proven diagnosis of TNBC in metastatic or locally advanced non operable
             stage

          -  EGFR expression in primary tumor or metastases of at least (1+) in
             immunohistochemistry, assessed by central pathologist

          -  Measurable or evaluable disease according to RECIST 1.1

          -  No prior systemic treatment for metastatic or inoperable disease

          -  Adequate bone marrow function: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L

          -  Adequate hepatic function: total bilirubin ≤ 1.5 x ULN; AST, ALT and AP ≤ 2.5 x ULN
             (AST, ALT and AP ≤ 5 x ULN if hepatic metastases are the only reason for enzyme
             elevation)

          -  Adequate renal function: serum creatinine ≤ 1.5 x ULN and calculated creatinine
             clearance &gt; 30 mL/min, according to the formula of Cockcroft-Gault.

          -  Adequate cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥ 40% as
             determined by either echocardiography (ECHO) or radionuclide angiocardiography (MUGA)

        Exclusion Criteria:

          -  Evidence of CNS or leptomeningeal metastases (even if previously treated); CNS imaging
             not required in asymptomatic patients

          -  History of hematologic or primary solid tumor malignancy, unless in remission for at
             least 5 years from registration. Inclusion of adequately treated cervical carcinoma in
             situ or localized non-melanoma skin cancer is permitted independent of time since
             diagnosis

          -  Previous therapy with more than 240 mg/m2 of doxorubicin or more than 450 mg/m2 of
             epirubicin

          -  Previous radiotherapy for the metastatic disease (palliative radiotherapy of only
             non-target lesions is allowed)

          -  Adjuvant treatment must have been stopped at least 6 months before registration

          -  Any serious underlying medical condition (at the judgement of the investigator) which
             could impair the ability of the patient to participate in the trial (e.g. active
             autoimmune disease, uncontrolled diabetes, etc.)

          -  Breastfeeding

          -  Participation in any investigational drug trial within 4 weeks preceding treatment
             start

          -  Any concomitant drugs contraindicated when administering Erbitux™ or Caelyx™ according
             to the Swissmedic-approved product information

          -  Known hypersensitivity to trial drug(s) or to any component of the trial drug(s)

          -  Any other serious underlying medical, psychiatric, psychological, familial or
             geographical condition, which in the judgment of the investigator may interfere with
             the planned staging, treatment and follow-up, affect patient compliance or place the
             patient at high risk from treatment-related complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Winterhalder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Luzerner Kantonsspital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Schneider</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Mamot, MD</last_name>
      <phone>+41 62 838 60 64</phone>
      <email>christoph.mamot@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Mamot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens B. Caspar, MD</last_name>
      <phone>41-56-486-2762</phone>
      <email>clemens.caspar@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Clemens Caspar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Rochlitz, Prof</last_name>
      <phone>+41 61 265 50 74</phone>
      <email>crochlitz@uhbs.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Rochlitz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Claraspital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Cescato, MD</last_name>
      <phone>+41 61 685 84 39</phone>
      <email>corinne.cescato@claraspital.ch</email>
    </contact>
    <investigator>
      <last_name>Corinne Cescato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urban Novak, MD</last_name>
      <phone>+41 31 632 19 92</phone>
      <email>urban.novak@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Urban Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Bodmer, MD</last_name>
      <phone>+41 22 372 40 14</phone>
      <email>alexandre.bodmer@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Alexandre Bodmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil Zaman, MD</last_name>
      <phone>41-21-314-4658</phone>
      <email>khalil.zaman@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Khalil Zaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Winterhalder, MD</last_name>
      <phone>+41 41 205 58 75</phone>
      <email>ralph.winterhalder@ksl.ch</email>
    </contact>
    <investigator>
      <last_name>Ralph Winterhalder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <phone>+41 62 311 42 41</phone>
      <email>cuhlmann_ol@spital.ktso.ch</email>
    </contact>
    <investigator>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Sion</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Membrez, MD</last_name>
      <phone>+41 27 603 48 53</phone>
      <email>veronique.membrez@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Véronique Membrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Hasler-Strub, MD</last_name>
      <phone>+41 71 494 19 32</phone>
      <email>ursula.hasler-strub@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Ursula Hasler-Strub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital STS AG</name>
      <address>
        <city>Thun</city>
        <zip>CH-3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rauch, MD</last_name>
      <phone>+41 33 226 26 45</phone>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkozentrum - Klinik im Park</name>
      <address>
        <city>Zurich</city>
        <zip>8002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Trojan, MD</last_name>
      <phone>+41 43 344 33 33</phone>
      <email>trojan@ist.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Trojan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Dedes, MD</last_name>
      <phone>+41 44 255 1613</phone>
      <email>Konstantin.dedes@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Konstantin Dedes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>advanced triple Negative, EGFR positive breast cancer</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>triple negative breast cancer (TNBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

